Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial

Abstract

ABSTRACT

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

“…In the study of Sansonno et al there was a longer time until disease progression in cirrhotic patients with hepatitis C and intermediate-stage HCC tumors treated with sorafenib starting 30 days after TACE [9]. Although in our sample most patients also presented hepatitis C-related cirrhosis, we had 40.54% of patients with Child-Pugh B whereas the trial of Sansonno et al was limited to Child-Pugh A patients.…”

“…Initial results seem encouraging, although there is a large heterogeneity of patients included in this type of combined treatment. One of the first randomized studies showed a longer time for the disease progression in patients with intermediate tumor stage [9]. Many other studies have been conducted worldwide, but when they are critically analyzed the authors have no doubts that more studies are needed to provide more reliable data about the indications of treatment combining TACE and sorafenib [10]- [12].…”

Yttrium-90 radioembolization for hepatocellular carcinoma in hepatitis B: commentary on a 103-patient Asian cohort

“…sorafenib) and in BCLC B (TACE/drug-eluting beads ? sorafenib), with the most encouraging results among a HCV alone cohort [16][17][18][19][20]. However, it is apparent that, with tumor progression, many patients develop hepatic decompensation, limiting the ability to initiate sorafenib [21,22].…”

ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study

“…Several clinical trials have been performed on the combined use of transarterial chemoembolization (TACE) and sorafenib [4,[30][31][32][33][34]. However, these studies did not succeed in their primary aim because patients were not selected on the basis of molecular markers.…”